Osimertinib for EGFR‐Mutant Lung Cancer with Brain Metastases: Results from a Single‐Center Retrospective Study

INTRODUCTION. Osimertinib is a third‐generation tyrosine kinase inhibitor, initially approved for epidermal growth factor receptor (EGFR) mutant non‐small cell lung cancer (NSCLC) with T790M acquired resistance, and now approved in the first‐line setting. However, data supporting the use of osimerti...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Xie, Lijia, Nagpal, Seema, Wakelee, Heather A., Li, Gordon, Soltys, Scott G., Neal, Joel W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2018
Soggetti:
Lung Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656518/
https://ncbi.nlm.nih.gov/pubmed/30126856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0264
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi